teserpaturev
AXP000002.1 · Oncolytic virus
- Platform
- HSV-1 (G47delta, triple-mutated: gamma34.5, ICP6, alpha47)
- Originator
- The University of Tokyo (Tomoki Todo)
- Sponsor
- Daiichi Sankyo
Names
| Name | Type | Source |
|---|---|---|
| teserpaturev | preferred name, INN | curator, ncit |
| Delytact | brand | press |
| DS-1647 | code | press |
| G47∆ | code | press |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- F
- Replication
- conditionally replicating
- Modifications
- both copies of RL1 (gamma34.5) deleted; UL39 (ICP6) inactivated by lacZ insertion; US12 (ICP47) deleted
- Transgenes
- LacZ
- Route
- intratumoral, intracerebral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C190358
- Wikidata
- Q116044341
- FDA UNII
- 6S57D3Y2F5
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| PMDA | JP | 2021-06-11 | conditional | Delytact | Malignant glioma (conditional, time-limited approval) | source |
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42885740 | Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR. | Oncotarget | 2026 | name in abstract: teserpaturev |
| PMID 36917020 | Regulatory Issues: PMDA - Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma. | The oncologist | 2023 | name in title: teserpaturev |
| PMID 35864115 | A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. | Nature communications | 2022 | name in title: G47∆ |
| PMID 35864254 | Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. | Nature medicine | 2022 | name in title: G47∆ |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41675687 | Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery. | Molecular therapy. Oncology | 2026 | name in abstract: teserpaturev |
| PMID 41901211 | Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: teserpaturev |
| PMID 42025901 | Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects. | Clinica chimica acta; international journal of clinical chemistry | 2026 | name in abstract: Delytact |
| PMID 42216079 | Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies. | Virology journal | 2026 | name in abstract: teserpaturev |
| PMID 42440296 | Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma: A Review. | JAMA neurology | 2026 | name in abstract: teserpaturev |
| PMID 43005928 | The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery. | RSC advances | 2026 | name in abstract: teserpaturev |
| PMID 40102594 | Author Correction: Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. | Nature medicine | 2025 | name in title: G47∆ |
| PMID 40285023 | Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus. | Viruses | 2025 | name in abstract: Delytact |
| PMID 40702727 | Oncolytic HSV and cancer drug interactions: Current clinical status and future directions. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: Delytact |
| PMID 40872965 | Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook. | Vaccines | 2025 | name in abstract: teserpaturev |
| PMID 40881284 | Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential. | Frontiers in microbiology | 2025 | name in abstract: teserpaturev |
| PMID 38896326 | An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas. | Current treatment options in oncology | 2024 | name in abstract: teserpaturev |
| PMID 39293238 | Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers. | Virology | 2024 | name in abstract: teserpaturev |
| PMID 36299168 | Oncolytic virus preclinical toxicology studies. | Journal of applied toxicology : JAT | 2023 | name in abstract: teserpaturev |
| PMID 36619294 | Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors. | Molecular therapy oncolytics | 2023 | name in title: G47∆ |
| PMID 37194509 | [Drugs under Development (Neurosurgery)]. | Brain and nerve = Shinkei kenkyu no shinpo | 2023 | name in abstract: Delytact |
| PMID 37583387 | Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models. | Molecular therapy oncolytics | 2023 | name in title: G47∆ |
| PMID 35384530 | Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. | Brain tumor pathology | 2022 | name in abstract: Delytact |
| PMID 35951174 | The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus infection in glioblastoma multiforme cancer stem cells. | Journal of neurovirology | 2022 | name in title: G47∆ |
| PMID 36098872 | Teserpaturev/G47Δ: First Approval. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2022 | name in title: teserpaturev |
| PMID 34675919 | Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. | Frontiers in immunology | 2021 | name in abstract: teserpaturev |
| PMID 34853811 | Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. | Molecular therapy oncolytics | 2021 | name in title: G47∆ |
| PMID 23292314 | The oncolytic herpes simplex virus vector G47∆ effectively targets breast cancer stem cells. | Oncology reports | 2013 | name in title: G47∆ |
Unconfirmed matches (18)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41403403 | Engineering HSV-1 for oncolytic therapy: From molecular entry mechanisms to retargeting strategies. | Genes & diseases | 2026 | name in abstract: G47∆ |
| PMID 41827827 | Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation. | Cells | 2026 | name in abstract: G47∆ |
| PMID 42648642 | Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience. | Virologica Sinica | 2026 | name in abstract: G47∆ |
| PMID 42886257 | Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives. | Clinical and experimental medicine | 2026 | name in abstract: G47∆ |
| PMID 40069043 | HSV-1 as a gene delivery platform for cancer gene therapy. | Trends in pharmacological sciences | 2025 | name in abstract: G47∆ |
| PMID 40957170 | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles. | International immunopharmacology | 2025 | name in abstract: G47∆ |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: G47∆ |
| PMID 41463198 | Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. | Cancers | 2025 | name in abstract: G47∆ |
| PMID 38599661 | Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. | Journal for immunotherapy of cancer | 2024 | name in abstract: G47∆ |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: G47∆ |
| PMID 36966232 | Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12. | Communications medicine | 2023 | name in abstract: G47∆ |
| PMID 35836877 | Advances in the clinical development of oncolytic viruses. | American journal of translational research | 2022 | name in abstract: G47∆ |
| PMID 34036669 | Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors. | Cancer science | 2021 | name in abstract: G47∆ |
| PMID 30462296 | Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. | Japanese journal of clinical oncology | 2019 | name in abstract: G47∆ |
| PMID 28326624 | Current status of clinical trials assessing oncolytic virus therapy for urological cancers. | International journal of urology : official journal of the Japanese Urological Association | 2017 | name in abstract: G47∆ |
| PMID 27486853 | Oncolytic virus therapy: A new era of cancer treatment at dawn. | Cancer science | 2016 | name in abstract: G47∆ |
| PMID 24575383 | Immunovirotherapy for the treatment of glioblastoma. | Oncoimmunology | 2014 | name in abstract: G47∆ |
| PMID 23754388 | Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. | Proceedings of the National Academy of Sciences of the United States of America | 2013 | name in abstract: G47∆ |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21NS130429 | Targeting CD44 signaling in regulating glioblastoma stemness and immune response | AUGUSTA UNIVERSITY | HONG, BANGXING B | 2023–2024 | name in abstract: Delytact |
| R21NS123685 | IGF1R-targeted oncolytic herpes simplex viral therapy for Glioblastoma | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | YOO, JI YOUNG | 2022–2023 | name in abstract: Delytact |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA163205 | Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy | BRIGHAM AND WOMEN'S HOSPITAL | KAUR, BALVEEN | 2023–2026 | name in abstract: G47∆ |
Notes
Conditionally approved in Japan 2021 as Delytact. No human transgene (LacZ marker in ICP6); targets left empty. Wikidata has a duplicate item Q110220405 (carries the UNII) beside Q116044341 (the English Wikipedia item).
How to cite
teserpaturev (AXP000002.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000002.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.